Next-gen Oncology: the Role of CAR-T Cells Against Ocular Lymphoma and Myeloma

Overview

Journal Eye (Lond)

Specialty Ophthalmology

Date 2024 Sep 12

PMID 39266617

Authors

Mouayad Masalkhi

Noura Wahhoud

Ezzat Elhassadi

Affiliations

Soon will be listed here.

References

Denton C, Gange W, Abdel-Azim H, Jodele S, Kapoor N, Oberley M . Bilateral retinal detachment after chimeric antigen receptor T-cell therapy. Blood Adv. 2020; 4(10):2158-2162. PMC: 7252550. DOI: 10.1182/bloodadvances.2020001450. View

Chan C, Wallace D . Intraocular lymphoma: update on diagnosis and management. Cancer Control. 2004; 11(5):285-95. PMC: 1971130. DOI: 10.1177/107327480401100502. View

Zhang X, Zhu L, Zhang H, Chen S, Xiao Y . CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. Front Immunol. 2022; 13:927153. PMC: 9226391. DOI: 10.3389/fimmu.2022.927153. View

Wang Y, Cao J, Gu W, Shi M, Lan J, Yan Z . Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma. J Clin Oncol. 2022; 40(20):2246-2256. DOI: 10.1200/JCO.21.01676. View

Alsarhani W, Abu El-Asrar A . Varicella Zoster Viral Retinitis following Chimeric Antigenic Response T-cell Therapy for B-cell Lymphoma. Ocul Immunol Inflamm. 2021; 30(6):1447-1448. DOI: 10.1080/09273948.2021.1889611. View

Eshhar Z, Waks T, Gross G, Schindler D . Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993; 90(2):720-4. PMC: 45737. DOI: 10.1073/pnas.90.2.720. View

Park J, Riviere I, Gonen M, Wang X, Senechal B, Curran K . Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):449-459. PMC: 6637939. DOI: 10.1056/NEJMoa1709919. View

Shoji M, Chen Y, Topilow N, Khzam R, Dubovy S, Johnson T . Orbital Involvement in Multiple Myeloma. Ophthalmic Plast Reconstr Surg. 2023; 39(4):347-356. DOI: 10.1097/IOP.0000000000002314. View

Zhang X, Zhang H, Lan H, Wu J, Xiao Y . CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies. Front Immunol. 2023; 14:1101495. PMC: 9986336. DOI: 10.3389/fimmu.2023.1101495. View

10.

Zhao Z, Chen Y, Francisco N, Zhang Y, Wu M . The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. Acta Pharm Sin B. 2018; 8(4):539-551. PMC: 6090008. DOI: 10.1016/j.apsb.2018.03.001. View

11.

Locke F, Ghobadi A, Jacobson C, Miklos D, Lekakis L, Oluwole O . Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2018; 20(1):31-42. PMC: 6733402. DOI: 10.1016/S1470-2045(18)30864-7. View

12.

Mei H, Li C, Jiang H, Zhao X, Huang Z, Jin D . A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. J Hematol Oncol. 2021; 14(1):161. PMC: 8501733. DOI: 10.1186/s13045-021-01170-7. View

13.

Cook M, Dorris C, Makambi K, Luo Y, Munshi P, Donato M . Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients. Blood Adv. 2022; 7(1):32-39. DOI: 10.1182/bloodadvances.2022008525. View

14.

Frey C, Cherniawsky H, Etminan M . Ocular adverse events following CAR-T cell therapy: A pharmacovigilance study and systematic review. Eur J Haematol. 2024; 113(1):66-71. DOI: 10.1111/ejh.14208. View

15.

Mumtaz A, Fischer A, Lutfi F, Matsumoto L, Atanackovic D, Kolanci E . Ocular adverse events associated with chimeric antigen receptor T-cell therapy: a case series and review. Br J Ophthalmol. 2022; 107(7):901-905. DOI: 10.1136/bjophthalmol-2021-320814. View